Genethon

[RECRUTEMENT ALTERNANCE] Envie d’une alternance en Contrôle de Gestion & Comptabilité H/F ? 🎓 Genethon accueille chaque année de jeunes talents prêts à s’engager dans un environnement scientifique innovant et porteur de sens. Au sein de la Direction Administration et Finance, l’alternant(e) contribuera à des missions variées en contrôle de gestion et comptabilité : suivi de trésorerie, préparation du CIR, analyse des coûts, amélioration des reportings financiers, clôtures comptables, suivi des subventions et opérations comptables courantes. 🔍 Ce que vous trouverez ici : · L'opportunité de contribuer concrètement à la performance d'un acteur engagé dans la lutte contre les maladies rares · Un environnement collaboratif où les métiers supports jouent un rôle clé au service de la recherche et de l'innovation · Une belle opportunité pour découvrir les métiers de la finance d’entreprise dans un l’environnement de la thérapie génique 📍 Alternance basée à Évry-Courcouronnes, à pourvoir dès octobre 2026. À découvrir ici 👉 https://lnkd.in/ee_R-8-h Les maladies rares ont besoin de talents singuliers. #recrutement #alternance #contrôledegestion #comptabilité #finance #nousrejoindre Da Cruz Jean Nathalie PROY Claire POLY

Would you like to be part of the future of genetic medicine? GenoTher, the French biocluster dedicated to #genetic medicine, launch its first Call for Expressions of Interest. As a founding partner, Genethon is committed to supporting the next generation of innovators developing breakthrough solutions in gene therapy, genome editing, cell therapy, therapeutic RNA and other areas. This unique acceleration programme offers selected #startups and SMEs access to funding, scientific expertise, industrial know-how and a powerful #network of partners to help transform innovation into tomorrow's therapies. 👇 Find out more below ! Don't miss this opportunity ! #GeneticMedicine #GeneTherapy #Biotech #Innovation #GenoTher

[PRESS RELEASE] 🔬 Behind every gene therapy milestone lies years of scientific, regulatory, and manufacturing excellence. We are proud to continue our collaboration with SK pharmteco and Yposkesi, an SK pharmteco company in support of GNT-0004, our investigational gene therapy for Duchenne muscular dystrophy. Together, we have built the manufacturing foundation that enabled the launch of the ongoing pivotal Phase III trial in Europe and the UK. A shared commitment to advancing innovative therapies for people living with rare diseases. 👉 Full press release: urlr.me/6cnbvq #GeneTherapy #DMD #RareDiseases #ClinicalTrials #Biomanufacturing Frederic Revah Joerg Ahlgrimm

📢 [NEWSLETTER – 2026 Issue #2] Genetic medicine has reached a pivotal moment: #science is delivering, and the challenge now is ensuring access for all patients. At Genethon, we are turning innovation into tangible therapeutic progress. 🚀 In this new edition: - Duchenne muscular dystrophy (#GNT0004): confirmed 2-year efficacy and safety with a low-dose approach designed for better scalability - LGMD-R5: promising early clinical results from Atamyo Therapeutics' ATA-200 gene therapy - Innovation: collaboration with Ampersand Biomedicines to develop next-generation, tissue-targeted AAV vectors - Leadership & collaboration: strong presence at global conferences and momentum from the GenoTher Summit to scale gene therapy 🔬 Beyond scientific breakthroughs, a key priority remains: overcoming challenges in delivery, manufacturing and access so that no patient is left behind. 👉 Explore the full newsletter: https://lnkd.in/eWYeeyaR #GeneTherapy #GeneticMedicine #RareDiseases #Innovation #ClinicalResearch #Biotech #AccessToTreatment #Collaboration #Duchenne #LGMD #AAV Frederic Revah Dion Foundation Isabelle Richard Barry Byrne Courtney Dion Joe Dion Angela Columbano Marco Pintore Maria Grazia BIFERI American Society of Gene & Cell Therapy Giuseppe Ronzitti Arnaud Valent Gérald Perret (Ph.D, MBA) Xavier Nissan Wael KHAZEN Mario Amendola AFM-Téléthon Dr Solange Corriol-Rohou, MD, PhD Teresinha Evangelista Sarah Abbas Alexandre Méjat Maëlle RALU, PhD Simon Guiraud Sumitava Dastidar Paola Galbiati Emilia Sadaoui Fetta MAZED - PhD Fatima AMOR Anne De Cian Giuseppe Ronzitti Francesco Saverio Tedesco CureSCG Rana Abu Khadra

Excited to be attending the 1st Società Italiana di Terapia Genica e Cellulare(SITGEC) Annual Meeting in Milan on July 17–18! On behalf of Genethon, I'll be presenting my poster on liver-directed gene therapy for hepatic Glycogen Storage Disease Type III (GSD III), showcasing both rAAV and lentiviral vector approaches, while providing insights into the biological factors that may affect long-term durability of transgene expression and disease correction in GSDIII mouse model liver. 📌 Poster P52 📌 "The Challenges of Liver-Directed Gene Therapy for Glycogen Storage Disease Type III" Come by if you'd like to discuss! Many thanks to my PI Giuseppe Ronzitti, my co-supervisor Fanny Collaud, and all the other authors who contributed to this work. See you in Milan!

🎆PANEL DISCUSSION ANNOUNCEMENT!🎆 Looking forward to this panel discussion at our upcoming Advanced Therapies USA Congress taking place this November in Boston! Moderator: Mukesh Mayani, PhD, P.Eng., Senior Director, Global CMC Development, Ultragenyx 🎤 Angela Columbano, Head of Business Development Partnership, Genethon 🎤 frederic bushman, Professor and Chair, Department of Microbiology, Co-Director PennCHOP Microbiome Program, Perelman School of Medicine, University of Pennsylvania 🎤 Roy Levitt, Clinical Professor, Director, UHealth Institute for Advanced Pain Management Center, University of Miami 🎤 Matt Edwards, MBA, Vice President, Process Science, Affinia Therapeutics 🎤 Daniel Cohen, Senior Director, Vector Engineering Genomics and Computational Biology, Roche Innovation Center For more information about all of our 200 speakers and the congress please go here: https://lnkd.in/g55Ywp2u #pharma #biotech #atmp #cell #gene #advancedtherapies #healthcare #lifesciences

🎓🔬 [STAGE DE SECONDE] À la découverte des métiers qui font avancer la thérapie génique. Pendant deux semaines, Genethon a eu le plaisir d'accueillir cinq élèves de seconde pour une immersion au cœur de nos activités de recherche, de développement et de support. Grâce à la mobilisation exceptionnelle de près de 40 collaborateurs, issus aussi bien des laboratoires que des fonctions support, les élèves ont pu découvrir la diversité des métiers et des expertises qui jalonnent le long chemin allant de la recherche au médicament. Cette démarche s'inscrit pleinement dans la volonté de Genethon de faire découvrir ses activités et ses métiers au plus grand nombre, en cohérence avec les valeurs de transparence portées par le Téléthon. Au programme : 🧬 Analyse d'ADN 🔬 Observation et manipulation de cellules 👩🔬 Découverte des techniques de laboratoire 🔎 Observation au microscope 🏢 Visite des laboratoires de Généthon et d'I-Stem 🤝 Rencontres avec de nombreux professionnels aux parcours variés Curieuses, attentives et très impliquées, ces jeunes stagiaires ont découvert qu'un projet de thérapie génique mobilise bien plus que les seuls métiers scientifiques : chercheurs, ingénieurs, techniciens, mais aussi les équipes projet, qualité, communication ou ressources humaines qui contribuent chaque jour à faire avancer notre mission. 👉Nos métiers: https://lnkd.in/e4fzJ9uQ Nous rejoindre: https://lnkd.in/eXRsjzZ6 Un grand merci à l'ensemble des équipes pour leur engagement et leur enthousiasme dans l'accompagnement de ces jeunes talents. Nous espérons que cette expérience aura nourri leur curiosité et, peut-être, fait naître quelques vocations. Parce que les maladies rares ont besoin de Talents Singuliers. ✨ #Généthon #StageDeSeconde #DécouverteDesMétiers #TalentsSinguliers #JeunesTalents #Recherche #ThérapieGénique #Téléthon #Orientation #ISTEM

[SYMPOSIUM] Genethon was proud to co‑organize, alongside Institut Imagine and the Broad Institute of MIT and Harvard, an exceptional symposium dedicated to the future of genetic medicine. This unique gathering brought together leading scientific, clinical and regulatory experts from these institutions to explore how the most advanced innovations in genetic medicine can be translated into transformative treatments for patients.   The symposium featured high-level presentations from pioneers and experts and, including Pr. David R. Liu (Broad Institute of MIT and Harvard, Harvard University, Howard Hughes Medical Institute (HHMI), Pr.Tim Yu, Romain Lévy, M.D, Ph.D, Marina Cavazzana, Frederic Revah, Annarita Miccio and Winston Yan, MD PhD, reflecting the depth and excellence of the discussions across disciplines.   As highlighted by Frederic Revah, “ This Symposium brought together the best experts from our institutions which are leading pioneers in the field of Genetic Medicine, and have been at the origin of world firsts in the field of gene therapy and genetic surgery from research to use in patients. »   Throughout the day, discussions also highlighted what it truly takes to move from breakthrough science to patient impact. - From the very first steps from the bench to first‑in‑human, experts, including Dr. Giuseppe Ronzitti, addressed the key challenges of preclinical proof of concept, quality control and safety. - The central role of patient organizations was also underscored, with the contribution of the Center for Therapeutic Genetics and the unique development of a cutting-edge innovation ecosystem built by AFM-Téléthon with François Lamy. - Then, the conversation extended to regulatory pathways, with a dedicated roundtable on strategies across France, Europe and the United States, moderated by Frédéric Revah, bringing together perspectives from major authorities with the major contribution of Catherine Paugam-Burtz (Catherine P.)  CEO of ANSM Agence nationale de sécurité du médicament et des produits de santé, Dr Emmely de Vries - European Medical Association (EMA). Medical Association for Doctors and Medical Industry Personnel. (EMA) and Winston Yan, MD PhD. - Finally, the question of sustainability was at the heart of discussions, with Vincent Genet contributing to a forward‑looking dialogue on building a robust economic model capable of ensuring long‑term access to genetic therapies.   At Genethon, we remain fully committed to advancing gene therapy and genome editing through collaboration, with one clear objective: bringing these innovations to as many patients as possible.   #genethon #GeneticMedicine #GeneTherapy #RareDiseases #PatientAdvocacy  Alexander Sousa Nina Frost Bernard Celli Emi Botelho Bana Jabri, Center for Therapeutic Genetics, Université Paris Cité, AP-HP, Assistance Publique - Hôpitaux de Paris  

"We are very much looking forward to welcoming you to Myology 2027 in the beautiful city of Strasbourg. Join us to present your latest research findings and discuss how we can shape the future of medicine in the field of neuromuscular diseases". Prof. @Hildegard Büning, Ph.D - Hannover Medical School Chairwoman of Myology2027 Congress